NCT00549874View on ClinicalTrials.gov

Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes

NACompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

February 28, 2002

Study Completion Date

November 30, 2006

Conditions

Type 2 Diabetes

Interventions

DRUG

Rosiglitazone

oral 8 mg/once daily for 6 months

DRUG

Glyburide

20 mg/ once daily for 6 months

Trial Locations (2)

43606

University of Toledo - Health Campus, Toledo

48109

University of Michigan, Ann Arbor

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Michigan

OTHER

NCT00549874 - Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes | Biotech Hunter | Biotech Hunter